This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Low Dose Continuous Administration of the Progesterone Receptor Modulator VA2914

This study has been completed.
Information provided by:
HRA Pharma Identifier:
First received: April 4, 2007
Last updated: June 16, 2010
Last verified: June 2010
The purpose of the present study is to evaluate continuous administration of low doses of VA2914 for potential contraceptive activity and effects on the menstrual cycle and steroid hormone parameters.

Condition Intervention Phase
Contraception Gynecologic Diseases Drug: VA2914 Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double
Primary Purpose: Treatment
Official Title: Prospective Randomized Multicenter Phase II Study of the Dose-Response Effects of Continuous Administration of Low-Dose VA2914 on Parameters of the Hypothalamic-Pituitary-Gonadal Axis and the Endometrium

Resource links provided by NLM:

Further study details as provided by HRA Pharma:

Primary Outcome Measures:
  • ovarian hormones
  • follicular development
  • endometrial histology

Secondary Outcome Measures:
  • menstural bleeding patterns
  • cervical mucus
  • VA2914 concentration
  • adverse events
  • laboratory parameters

Estimated Enrollment: 48
Study Start Date: January 2004
Study Completion Date: December 2004

Ages Eligible for Study:   18 Years to 35 Years   (Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • women in good general health with regular, ovulatory menstrual cycles
  • age 18-35
  • not pregnant
  • not sexually active or reliably use barrier methods of contraception
  • normal liver and renal functions and normal laboratory exams

Exclusion Criteria:

  • pregnant or breastfeeding
  • oral contraception, IUD or other hormonal treatment
  • use of agents known to induce hepatic P450
  • cardiovascular disorder
  • hepatic, renal, or gastrointestinal disorder
  • metrorrhagia
  • abnormal transvaginal ultrasound (at baseline)
  • history of abnormal endometrial biopsy,
  • cancer
  • depression
  • mental illness
  • epilepsy
  • migraines
  • abnormal Pap Smear requiring further exploratory examination
  • anovulatory cycle before treatment
  • extreme overweight or underweight (body mass index < 16 ou >28)
  • subjects unlikely to comply with the protocol, e.g., uncooperative attitude, inability to return for follow-up visits, and unlikelihood of completing the study
  • use of narcotics
  • more than 10 cigarettes per day, more than 2 glasses of wine/beer per day
  • surgical procedures planned in the 6 months following screening visit
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00456924

Liege University Hospital
Liege, Belgium
Sainte Rosalie Clinique
Liege, Belgium
Antoine Beclere Hospital
Clamart, France
Saint Antoine Hospital
Paris, France
Sponsors and Collaborators
HRA Pharma
Principal Investigator: Philippe Bouchard, MD Saint Antoine Hospital, Paris, France
  More Information

Publications: Identifier: NCT00456924     History of Changes
Other Study ID Numbers: 2914-002
Study First Received: April 4, 2007
Last Updated: June 16, 2010

Keywords provided by HRA Pharma:
progesterone receptor modulator

Additional relevant MeSH terms:
Genital Diseases, Female
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs processed this record on September 19, 2017